2023-05-30 10:08:44
The Korean Pharmaceutical Association expressed strong concerns regarding the ‘non-face-to-face treatment’ pilot project that will be implemented from the 1st of next month.
The Pharmaceutical Association pointed out today (30th), ″If non-face-to-face treatment is allowed hastily as it is now, the harm caused by misdiagnosis, excessive treatment, and misuse of medicines will be concentrated on the medically vulnerable class, such as those with mobility difficulties.″
He continued, “It seems that the non-face-to-face treatment pilot project was rushed by something without sufficient review or evaluation.”
In particular, the Pharmaceutical Association argued that ″a regulatory mechanism for intermediary platform companies has not been sufficiently prepared″ and that ″abnormal treatment and illegal delivery of medicines may be rampant.″
At the same time, ″For patients with diseases other than chronic diseases, unlimited non-face-to-face treatment is allowed for return visits within 30 days, and there are no restrictions on prescriptions for non-essential and non-reimbursable medicines such as hair loss and acne, or practical sanctions against illegal acts by platform companies. ″ was pointed out as an urgent problem.
The pharmacist association also argued that the fact that fax or e-mail prescriptions were allowed in the pilot project, that identification procedures were not specifically presented when receiving drugs by proxy or at home, and that the end date of the pilot project was not specified were also problems.
However, the pharmacist association evaluated that it was ″fortunate out of misfortune″ that the scope of home pickup of medicines was minimized.
1685455579
#Pharmacist #Association #nonfacetoface #treatment #allowed #medically #vulnerable #harmed